{"query":"immatics.com","mode":"domain","best":{"domain":"immatics.com","status":"valid","tier":"listed","authority":50,"verified":false,"title":"Immatics: The global leader in precision targeting of PRAME","summary":"Immatics is developing novel immunotherapies to recognize and eliminate cancer cells that present PRAME. They have the broadest PRAME franchise with the most indications and therapeutic modalities.","country":"US","country_source":"ip","llms_txt":"https://www.immatics.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-20T08:29:30.752Z","agent_terms":null,"categories":["healthcare","science-research"],"capabilities":[],"inferred_tags":["prame immunotherapy","cancer immunotherapy","t cell receptor therapy","oncology pipeline","biotech"],"audience":"mixed","agent_uses":["read_docs"],"language":"en","platform_generated":false,"agent_summary":"Immatics, a biotech developing PRAME-targeted cancer immunotherapies; covers science, pipeline, publications, leadership and company information.","llms_txt_cached":"https://agentwebmap.com/v1/domain/immatics.com/llms.txt","agentic":"documentation","section_keys":["careers","clinical-trials","company-overview","news-and-contact-information","the-science-and"],"section_partial":false,"section_indexed_at":"2026-10-22T21:29:46.534Z","why":["authority 50 (listed)","checked 3758 minutes ago"]},"read":{"llms_txt":"https://www.immatics.com/llms.txt","llms_full_txt":null,"nested_llms_txt":[]},"terms":null,"health":{"ok":true,"status":"valid","tier":"listed","authority":50,"last_checked":"2026-10-20T08:29:30.752Z","checked_minutes_ago":3757,"stale":true,"max_age_seconds":86400,"live_checked":false,"http_status":200,"last_valid":"2026-10-20T08:29:30.752Z","content_hash":"86b0cd6b36340f64ab57ba807b4d5f70"},"sources":[],"match":{"strength":"domain","reason":"Exact domain or its registered publisher."},"provenance":{"selection":"directory","verification":"domain_ownership","terms":"unknown","excerpts":"publisher_link_metadata","health":"stored_crawl"},"alternatives":[]}